Home The Word Brain My Amedeo FAQ Privacy About


Hanzi Hunter

Learning 500 Chinese characters in 30 days is possible.

Abstract • About

  Bladder Cancer

  Free Subscription


23.02.2026

1 Adv Anat Pathol
2 Aktuelle Urol
1 Ann Surg Oncol
1 Biol Pharm Bull
1 BJU Int
2 BJUI Compass
1 Cancer Lett
1 Cancer Res
1 Cell
1 Cell Signal
1 Eur Urol
1 Eur Urol Oncol
1 FEMS Microbiol Lett
1 Front Cell Infect Microbiol
1 Front Microbiol
1 Front Oncol
1 HPB (Oxford)
1 Int J Surg
1 Int J Urol
3 iScience
1 J Clin Pathol
1 J Pediatr Urol
1 J Transl Med
2 J Urol
1 JMIR Perioper Med
1 Jpn J Clin Oncol
1 Life Sci Alliance
2 Minerva Urol Nephrol
1 N Engl J Med
1 Nanoscale
1 Photodiagnosis Photodyn Ther
1 PLoS One
1 Proc Natl Acad Sci U S A
1 Urol Ann
2 Urol Oncol
1 World J Mens Health
1 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Adv Anat Pathol

  1. BASAR M, Yol C, Chen JF, Al-Ahmadie H, et al
    Micropapillary Urothelial Carcinoma: A Review and Update.
    Adv Anat Pathol. 2026;33:e1-e8.
    PubMed         Abstract available


    Aktuelle Urol

  2. NIEGISCH G, Zschabitz S, Klumper N, Eckstein M, et al
    [Current and future treatment stratification of metastatic urothelial carcinoma: a great opportunity for true precision oncology].
    Aktuelle Urol. 2026;57:46-51.
    PubMed         Abstract available

  3. LANGE F, Gaisa NT, Bolenz C, Klumper N, et al
    [Pathological Risk Stratification of Non-Muscle-Invasive and Muscle-Invasive Urothelial Carcinoma for Optimal Therapeutic Decision-Making].
    Aktuelle Urol. 2026;57:52-59.
    PubMed         Abstract available


    Ann Surg Oncol

  4. LIU Q, Lu X, He C, Chen J, et al
    Correction: A Novel Model for Muscle-Invasive Bladder Cancer Diagnosis Using Contrast-Enhanced Ultrasound.
    Ann Surg Oncol. 2026 Feb 16. doi: 10.1245/s10434-026-19331.
    PubMed        


    Biol Pharm Bull

  5. OKADA N, Kimura H, Ozaki M, Tamura M, et al
    Risk Factor of Persistent Hypotension Associated with 5-Aminolevulinic Acid: A Single-Institution Retrospective Study.
    Biol Pharm Bull. 2026;49:335-340.
    PubMed         Abstract available


    BJU Int

  6. AMER ML, Amer AR, Elnasharty SF, Homouda AA, et al
    Impact of perioperative nutrition on recovery after radical cystectomy: a randomised trial.
    BJU Int. 2026;137:536-546.
    PubMed         Abstract available


    BJUI Compass

  7. FUKUHARA H, Shigehisa R, Yamamoto S, Fukata S, et al
    Effect of extending the oral administration period of 5-aminolevulinic acid on diagnostic accuracy and treatment outcomes for non-muscle-invasive bladder cancer.
    BJUI Compass. 2026;7:e70173.
    PubMed         Abstract available

  8. CHEN KY, Jones MK, Ghosal S, Ignozzi GP, et al
    Predictors of adherence to surveillance cystoscopy for patients with non-muscle invasive bladder cancer.
    BJUI Compass. 2026;7:e70135.
    PubMed         Abstract available


    Cancer Lett

  9. SUN Y, Tong H, Zhao G, Wu L, et al
    Nutrient Deprivation Promotes Bladder Cancer Metastasis through Beclin-1 Deacetylation-Mediated Autophagy Activation.
    Cancer Lett. 2026 Feb 16:218337. doi: 10.1016/j.canlet.2026.218337.
    PubMed         Abstract available


    Cancer Res

  10. LUO W, Wang Y, Wang H, Ji YA, et al
    CCL5hi-CD4+ T cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer.
    Cancer Res. 2026 Feb 18. doi: 10.1158/0008-5472.CAN-25-2220.
    PubMed         Abstract available


    Cell

  11. JONAS K, Moser T, Heitzer E
    Listening to the bladder field: Urine liquid biopsies reveal differential treatment responses in NMIBC.
    Cell. 2026;189:995-997.
    PubMed         Abstract available


    Cell Signal

  12. GAO J, Pan Y, Cheng Q, Wang S, et al
    USP43 promotes lymphatic metastasis of bladder cancer by regulation of ZBTB7A.
    Cell Signal. 2026 Feb 18:112433. doi: 10.1016/j.cellsig.2026.112433.
    PubMed         Abstract available


    Eur Urol

  13. SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
    Corrigendum to "Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials" [Eur. Urol. (2025)].
    Eur Urol. 2026 Feb 17:S0302-2838(26)00063-1. doi: 10.1016/j.eururo.2026.
    PubMed        


    Eur Urol Oncol

  14. LONGONI M, Scilipoti P, De Angelis M, Zaurito P, et al
    Real-world Adherence to European Association of Urology-recommended Non-muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological Outcomes.
    Eur Urol Oncol. 2026 Feb 19:S2588-9311(26)00042.
    PubMed         Abstract available


    FEMS Microbiol Lett

  15. ACCETTO T, Strasek Smrdel K, Taskovska M, Starcic Erjavec M, et al
    Negative-control-anchored urinary microbiome profiling with absolute 16S quantification: a pilot study in newly diagnosed, treatment-naive bladder cancer and healthy individuals.
    FEMS Microbiol Lett. 2026 Feb 17:fnag020. doi: 10.1093.
    PubMed         Abstract available


    Front Cell Infect Microbiol

  16. PAN S, Zhu H, Yin R, Lin J, et al
    Carcinogen metabolism and bladder cancer: role of gut microbiota in disease and prevention.
    Front Cell Infect Microbiol. 2026;15:1727550.
    PubMed         Abstract available


    Front Microbiol

  17. LIU X, Chen Z, Lu Y, Wu Y, et al
    Fecal microbiota transplantation: a novel strategy and challenges in the adjuvant treatment of bladder Cancer.
    Front Microbiol. 2026;17:1756107.
    PubMed         Abstract available


    Front Oncol

  18. SONG F, Su S, Zhang X, Cao Y, et al
    A nomogram based on the red cell distribution width to lymphocyte ratio as a prognostic tool for non-muscle-invasive bladder cancer: a retrospective study.
    Front Oncol. 2026;16:1728821.
    PubMed         Abstract available


    HPB (Oxford)

  19. LAHIRI A, Chowdhury S, Goel S, Assif Iqbal S, et al
    Neoadjuvant therapy in gall bladder cancer improves resectability and survival: a prospective study.
    HPB (Oxford). 2026 Feb 2:S1365-182X(26)00016-X. doi: 10.1016/j.hpb.2026.
    PubMed         Abstract available


    Int J Surg

  20. XU C, Dong Y, Li J, Liao X, et al
    Integrating machine learning and mendelian randomization for identifying genetic biomarkers in bladder cancer: implications for early diagnosis and targeted therapies.
    Int J Surg. 2025 Dec 3. doi: 10.1097/JS9.0000000000003833.
    PubMed         Abstract available


    Int J Urol

  21. KUSANO S, Tobu S, Yukimoto M, Yamaguchi Y, et al
    Palliative Intra-Arterial Chemotherapy Without Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Comparison With Radical Cystectomy and Best Supportive Care.
    Int J Urol. 2026;33:e70386.
    PubMed         Abstract available


    iScience

  22. ZHANG J, Wang J, Hu X, Jia W, et al
    Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth.
    iScience. 2026;29:114786.
    PubMed         Abstract available

  23. HUANG X, Meng Y, Song J, Zhu Y, et al
    KNSTRN knockdown impairs autophagy flux to inhibit bladder cancer progression.
    iScience. 2026;29:114734.
    PubMed         Abstract available

  24. HU J, Zhu Y, Wang G, Dai H, et al
    SNW1 promotes lymphatic metastasis in bladder cancer by modulating SRPK1 splicing.
    iScience. 2026;29:114811.
    PubMed         Abstract available


    J Clin Pathol

  25. WEBER TD, Gershman B, Wang L, Rosen S, et al
    Rapid evaluation of muscularis propria in transurethral resection of bladder tumour specimens using non-linear microscopy (NLM).
    J Clin Pathol. 2026;79:186-191.
    PubMed         Abstract available


    J Pediatr Urol

  26. WEIR S, Murgas KA, Froehlich M, Nash M, et al
    Urothelial cell carcinoma of the bladder in pediatric patients: A comparison with adults from the National Cancer Database.
    J Pediatr Urol. 2026;22:105677.
    PubMed         Abstract available


    J Transl Med

  27. ZHANG H, Han S, Su Z, Zheng Z, et al
    Single-cell transcriptomic analysis and machine learning identify ATAD3A as a key gene that stabilizes mitochondrial-endoplasmic reticulum membranes, promoting bladder cancer progression.
    J Transl Med. 2026 Feb 20. doi: 10.1186/s12967-026-07857.
    PubMed         Abstract available


    J Urol

  28. RITCH C, Anderson CB
    Cystoscopic Fulguration for Patients with Recurrent Low-Grade Bladder Cancer.
    J Urol. 2026 Feb 18:101097JU0000000000004974. doi: 10.1097/JU.0000000000004974.
    PubMed        

  29. ZHANG S, Li T, Li D, Yin Y, et al
    Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined with Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial.
    J Urol. 2026 Feb 17:101097JU0000000000004993. doi: 10.1097/JU.0000000000004993.
    PubMed         Abstract available


    JMIR Perioper Med

  30. CAUSIO FA, De Vita V, Nappi A, Sawaya M, et al
    Survival Prediction in Patients With Bladder Cancer Undergoing Radical Cystectomy Using a Machine Learning Algorithm: Retrospective Single-Center Study.
    JMIR Perioper Med. 2026;9:e86666.
    PubMed         Abstract available


    Jpn J Clin Oncol

  31. KATO M, Matsue T, Yamamoto S, Yukimatsu N, et al
    Clinical impact of carboplatin-based neoadjuvant chemotherapy: lack of benefit and surgical delay in muscle-invasive bladder cancer.
    Jpn J Clin Oncol. 2026 Feb 19:hyag027. doi: 10.1093.
    PubMed         Abstract available


    Life Sci Alliance

  32. HINLEY J, Baker SC, Mason AS, Kyriazis G, et al
    Connexin 32 constrains a mesenchymal-like switch in differentiated urothelium and luminal cancers.
    Life Sci Alliance. 2026;9:e202503427.
    PubMed         Abstract available


    Minerva Urol Nephrol

  33. LAMBERTINI L, Saladino M, DI Maida F, Grosso AA, et al
    Oncologic outcomes after robot assisted radical cystectomy in patients with clinically positive lymph nodes (cN1): a tertiary referral center experience.
    Minerva Urol Nephrol. 2026;78:118-126.
    PubMed         Abstract available

  34. CRESTANI B, Tamborrino V, Bertolo R, Antonelli A, et al
    Balancing maternal and fetal safety in non-muscle-invasive bladder cancer: report of our experience.
    Minerva Urol Nephrol. 2026;78:155-157.
    PubMed        


    N Engl J Med

  35. VULSTEKE C, Adra N, Danchaivijitr P, Sabadash M, et al
    Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
    N Engl J Med. 2026 Feb 18. doi: 10.1056/NEJMoa2511674.
    PubMed         Abstract available


    Nanoscale

  36. ZHANG P, Xiong W, Wang K, Zhao X, et al
    Copper-based architectures for bladder cancer therapy: mechanistic insights, progress and prospects.
    Nanoscale. 2026 Feb 19. doi: 10.1039/d5nr04072.
    PubMed         Abstract available


    Photodiagnosis Photodyn Ther

  37. LI H, Long G, Hu L, Wang Q, et al
    Intravesical hematoporphyrin photodynamic therapy combined with pirarubicin for intermediate and high-risk non-muscle-invasive bladder cancer: a multicenter, prospective single-arm cohort.
    Photodiagnosis Photodyn Ther. 2026 Feb 14:105396.
    PubMed         Abstract available


    PLoS One

  38. SHEN J, Zhao Z, Li Z, Wang R, et al
    Bladder cancer-induced CVD mortality: Role of CAPG protein.
    PLoS One. 2026;21:e0338101.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  39. GALSKY MD, Izadmehr S, Yu M, Curtis SD, et al
    Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2533449123.
    PubMed         Abstract available


    Urol Ann

  40. INDRASWARI MT, Rahman F, Hamid ARAH, Mochtar CA, et al
    Psychological distress among bladder cancer patients: A systematic review.
    Urol Ann. 2026;18:10-17.
    PubMed         Abstract available


    Urol Oncol

  41. QU M, Wei J, Mo J, Chen J, et al
    Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.
    Urol Oncol. 2026;44:110970.
    PubMed         Abstract available

  42. DAS M, Rath S, Gorepatti R, Dash R, et al
    Microbiome-linked transcriptomic signatures in NMIBC: Toward personalized uro-oncology.
    Urol Oncol. 2026;44:110977.
    PubMed         Abstract available


    World J Mens Health

  43. KWON J, Jeon J, Lee HS, Jeon S, et al
    Effects of Radiation Therapy on the Incidence of Bladder Cancer and Rectal Cancer in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in Korean Population.
    World J Mens Health. 2026 Jan 15. doi: 10.5534/wjmh.250298.
    PubMed         Abstract available


    World J Urol

  44. KOHLER J, Buck L, Hugelmann K, Incesu RB, et al
    Chronological and biological age stratify survival after robot-assisted radical cystectomy for bladder cancer: a pragmatic age-ECOG risk score.
    World J Urol. 2026;44:178.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum